Scientific research groups












            ******************************************************************************************

            * Cardiovascular Pharmacology - CardioTox In Vivo
            ******************************************************************************************
            Head doc. PharmDr. Martin Štěrba, PhD. [ URL "https://is.cuni.cz/webapps/whois2/osoba/1080

            lang=cs"] The cardiotoxicity of anthracycline cytostatics has been studied with the aim to
            molecular mechanisms responsible for this organ-specific toxicity and subsequently the car
            effect of the evaluated compounds.

            Our research group focuses on the cardiovascular toxicity of anticancer drugs and the poss
            pharmacological cardioprotection in vivo. Our primary interest is in the cardiotoxicity of
            cytostatics (e.g., doxorubicin or daunorubicin) and, more recently, in the toxicity of new

            targeted drugs (e.g., tyrosine kinase inhibitors or proteasome inhibitors). In particular,
            to elucidate the molecular mechanisms responsible for developing this organ-specific toxic

            consequently, for the cardioprotective effect of the studied compounds. Our goal is to pro
            experimental and translational research in cardio-oncology.


            More about CardioTox In Vivo [ URL "LFHKEN-278.html "]




            ******************************************************************************************
            * Hepatic Pharmacology - LivPharm.

            ******************************************************************************************
            Head prof. MUDr. Stanislav Mičuda, PhD. [ URL "https://is.cuni.cz/webapps/whois2/osoba/157
            lang=cs"] The aim is to experimentally identify the potential therapeutic effect of variou

            in basic liver pathologies such as non-alcoholic steatohepatitis or intrahepatic cholestas
            hepatotoxicity and the risk of drug interactions are also studied for new agents.
            Main research focus is the evaluation of factors responsible for variability in hepatic dr

            with special attention paid to drug-drug and drug-food/natural product interactions. Assoc
            is the study of the physiology and pathology of bile formation, and consequent therapeutic
            for nonalcoholic fatty liver disease, and various cholestatic liver diseases including tho

            various xenobiotics.

            More about LivPharm. [ URL "LFHKEN-279.html "]





            ******************************************************************************************
            * Clinical Pharmacology - ClinPharm.
            ******************************************************************************************

            Head doc. Ing. Jaroslav Chládek, PhD. [ URL "https://is.cuni.cz/webapps/whois2/osoba/16574
            lang=cs"] Uses methods of individual and population modelling of pharmacokinetics and phar
            bioindicators of therapeutic and toxic effects of drugs for individualization of pharmacot

            We focus on the usage of individual and population modelling of pharmacokinetics, pharmaco
            and bio-indicators of therapeutic and toxic effects of drugs for individualization in phar
            In the field of clinical pharmacology, we have been cooperating for 15 years with the Depa

            Dermatology and Venereology at the University Hospital Hradec Králové on the topic of meth
            curing focal psoriasis. Other areas of clinical pharmacology research are the treatment of
            juvenile arthritis, Crohn’s disease, and the usage of non-invasive methods of examining bi

            respiratory tract disease with inflammation.